Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
Authors:
Open Access
- 1 July 2012
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. 8, 301-311
Abstract
Background: We evaluated the effects of once-daily extended-release quetiapine fumarate (quetiapine XR) on patient-reported outcomes in generalized anxiety disorder (GAD). Methods: This is a report of a pooled analysis from three acute 8-week, randomized, placebo-controlled, fixed-dose (50, 150, 300 mg/day) studies and a 52-week maintenance flexible dose (50–300 mg/day) study of quetiapine XR monotherapy in patients with GAD. Quality of Life Enjoyment and Satisfaction Questionnaire Short Form (Q-LES-Q-SF) percent maximum total scores (items 1–14), item 15 ("satisfaction with medication"), item 16 ("overall life satisfaction"), and Pittsburgh Sleep Quality Index (PSQI) global scores are reported. Sheehan Disability Scale (SDS) total scores were also assessed (maintenance study only). Results: The acute studies showed significant improvements at week 8 in Q-LES-Q-SF percent maximum total score with quetiapine XR 150 mg/day (P < 0.001) and item 16 with quetiapine XR 50 (P < 0.05) and 150 mg/day (P < 0.001) versus placebo; PSQI global scores significantly improved with quetiapine XR 50, 150, and 300 mg/day versus placebo (P < 0.001). The maintenance study showed significant benefits versus placebo with quetiapine XR 50–300 mg/day in Q-LES-Q-SF percent total score, item 15 and item 16 scores, PSQI global score, and SDS total score. Conclusion: Quetiapine XR 150 mg/day (acute studies) and 50–300 mg/day (maintenance study) improved quality of life, overall functioning, and sleep quality in patients with GAD.Keywords
This publication has 43 references indexed in Scilit:
- Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8‐week placebo‐controlled studiesHuman Psychopharmacology: Clinical and Experimental, 2011
- Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorderInternational Clinical Psychopharmacology, 2011
- Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: A flexible-dose, open-label pilot trialJournal of Anxiety Disorders, 2008
- Examining quality of life in patients with generalized anxiety disorder: Clinical relevance and response to duloxetine treatmentJournal of Psychiatric Research, 2008
- Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute SchizophreniaThe Journal of Clinical Psychiatry, 2007
- Duloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studies.2007
- Generalized anxiety disorder: A comorbid diseaseEuropean Neuropsychopharmacology, 2006
- Insomnia and generalized anxiety disorder:Journal of Anxiety Disorders, 2004
- Comparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disorders.1999
- Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure.1993